Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2019
ICER issues final report and policy recommendations on esketamine for treatment-resistant depression
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, ...
Posted by Michael Wonder on 20 Jun 2019
Institute for Clinical and Economic Review issues final report and policy recommendations on siponimod for secondary progressive multiple sclerosis
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate siponimod offers superior effectiveness for patients ...
Posted by Michael Wonder on 20 Jun 2019
Boston drug pricing watchdog group has pharma companies’ attention
19 June 2019 - His adversaries call him a shill for health insurers, a bloodless bean counter who would rather ...
Posted by Michael Wonder on 18 Jun 2019
Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price
18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...
Posted by Michael Wonder on 15 Jun 2019
Asthma and Allergy Foundation of America elevates patient voice in ICER review of new peanut allergy treatments
14 June 2019 - On June 11 in Oakland, CA the Institute for Clinical and Economic Review and its California Technology ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...
Posted by Michael Wonder on 13 Jun 2019
Aimmune wins over ICER for peanut allergy product
12 June 2019 - Analysts predict blockbuster status for first-in-class. ...
Posted by Michael Wonder on 08 Jun 2019
ICER to assess treatments for acute migraine
7 June 2019 - Report will be subject of Midwest CEPAC meeting in January 2020; open input now being accepted until ...
Posted by Michael Wonder on 28 May 2019
ICER’s assessment highlights the risk-benefit tradeoffs of investigational treatments for peanut allergy
28 May 2019 - To achieve commonly cited thresholds for cost-effectiveness, the annual price would need to be between $4,800-$7,200 for ...
Posted by Michael Wonder on 25 May 2019
ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy
24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...
Posted by Michael Wonder on 22 May 2019
ICER releases draft evidence report on treatments for Duchenne muscular dystrophy
22 May 2019 - Public comment period now open until June 18, 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 13 May 2019
Congress should revive the Office of Technology Assessment
13 May 2019 - In recent decades, the U.S. economy and society have been propelled forward by a boom in science ...
Posted by Michael Wonder on 10 May 2019
Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds
9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting. ...
Posted by Michael Wonder on 03 May 2019
ICER publishes evidence report on the use of siponimod to treat secondary progressive multiple sclerosis
2 May 2019 - Midwest CEPAC to deliberate on the treatment’s clinical effectiveness and other potential benefits during its May ...